Janssen

News

J&J joins COVID-19 booster shot drive, filing with FDA

Johnson & Johnson's COVID-19 vaccine has been a minor player in the US vaccination drive so far, but the company hopes it can have a bigger role as a booster shot.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J bulks up in bispecifics with $1.3bn Xencor alliance

Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with a deal to license a drug for B-cell cancers developed by Xencor.

Sales & Marketing

Creating a successful and productive partnership

EFPIA: Partnership is the key to healthcare’s biggest challe...

The European pharma body’s new Health Collaboration Guide hopes to inspire greater partnership working across healthcare, showcasing award-winning collaborations involving Pfizer, Janssen,

Sales & Marketing

Preparing for a post-pandemic world

Janssen’s Mark Hicken, VP of strategy, EMEA, looks at what COVID-19 has taught us and how we can become stronger as we emerge from the pandemic.

News

FDA clears J&J's twice-yearly Invega for schizophrenia

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson's pharma unit Janssen is trumpeting a new version of its Invega drug that

News

NICE rejects J&J's Darzalex regimen for multiple myeloma

New guidance from NICE has rejected a combination regimen based on Johnson & Johnson's Darzalex for a group of previously-untreated patients with multiple myeloma, a type of bone marrow

J&J joins COVID-19 booster shot drive, filing with FDA

J&J bulks up in bispecifics with $1.3bn Xencor alliance

EFPIA: Partnership is the key to healthcare’s biggest challe...

Preparing for a post-pandemic world

FDA clears J&J's twice-yearly Invega for schizophrenia

NICE rejects J&J's Darzalex regimen for multiple myeloma

CDMOs: Their crucial role and how to select one, with Sigma ...

How to meet your physicians where they are online

Janssen

Editor's Picks